ImmuPharma plc (LON:IMM – Get Free Report)’s stock price dropped 4.5% during trading on Wednesday . The stock traded as low as GBX 2.82 ($0.03) and last traded at GBX 2.94 ($0.04). Approximately 2,099,809 shares were traded during trading, a decline of 89% from the average daily volume of 19,547,262 shares. The stock had previously closed at GBX 3.08 ($0.04).
ImmuPharma Price Performance
The firm has a market cap of £16.99 million, a PE ratio of -408.00 and a beta of 1.53. The company has a 50-day simple moving average of GBX 1.71 and a 200-day simple moving average of GBX 1.72.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Differences Between Momentum Investing and Long Term Investing
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- The 3 Best Blue-Chip Stocks to Buy Now
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
